A randomised, double-blind, placebo-controlled trial found the vaginal microbicide Carraguard unable to prevent HIV infection. A substudy assessed the association of genital high-risk human papillomavirus (HR-HPV) in women at study end with Carraguard use.
Methods
Participants received Carraguard gel or placebo plus condoms, and were instructed to use gel plus condoms during each act of vaginal intercourse. HR-HPV detection on cervical samples from 1,723 women was by Digene Hybrid Capture 2 analysis. Poisson regression analysis assessed the prevalence of genital HR-HPV for individuals receiving Carraguard relative to individuals receiving placebo.
Results
In the Carraguard arm (n=875) the end trial unadjusted HR-HPV prevalence was 23.5% (95% CI 20.8– 26.3) and 23.0% (95% CI 20.2–25.8) in placebo arm (n=843). Significant risk factors for HR-HPV infection were younger age, being single, an abnormal pap smear, multiple sexual partners and promiscuous behaviour without the use of a condom. There were 348 compliant women (174 Carraguard, 174 placebo users), with relatively high adherence to gel use, who inserted 80% of their opened, returned applicators of test product with the proportion of applicator insertions to sex acts >30%. After adjusting for risk factors, these compliant Carraguard users were 0.62 as likely to be classified HR-HPV positive (95% CI 0.41–0.94) as compliant placebo users.
Conclusions
The prevalence of HR-HPV infection was lower in compliant Carraguard users than compliant placebo users. To our knowledge, this is the first report showing a negative association of HPV infection with a vaginal microbicide.
References
1.
SitasF., BlaauwD., TerblancheM., MadhooJ., CarraraH.Incidence of histological diagnosed cancer in South Africa, 1992. Johannesburg: National Cancer Registry of South Africa, South African Institute for Medical Research1998.
2.
HakimA.A., DinhT.A.Worldwide impact of the human papillomavirus vaccine. Curr Treat Options Oncol2009; 10: 44–53.
3.
MuñozN., BoschF.X., de SanjoséS.. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med2003; 348: 518–527.
4.
MorrisG.C., LaceyC.J.Microbicides and HIV prevention: lessons from the past, looking to the future. Curr Opin Infect Dis2010; 23: 57–63.
5.
Abdool KarimQ., Abdool KarimS.S., FrohlichJ.A.Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010; 329: 1168–1174.
6.
MaraisD., CarraraH., KayP., RamjeeG., AllanB., WilliamsonA.L.The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers. Virus Res2006; 121: 220–222.
7.
RobertsJ.N., BuckC.B., ThompsonC.D.Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med2007; 13: 857–861.
8.
BuckC.B., ThompsonC.D., RobertsJ.N., MullerM., LowyD.R., SchillerJ.T.Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog2006; 2: e69.
9.
Pérez-AndinoJ., BuckC.B., RibbeckK.Adsorption of human papillomavirus 16 to live human sperm. PLoS ONE2009; 4: e5847.
10.
HowettM.K., KuhlJ.P.Microbicides for prevention of transmission of sexually transmitted diseases. Curr Pharm Des2005; 11: 3731–3746.
11.
ChristensenN.D., ReedC.A., CulpT.D.Papillomavirus microbicidal activities of high-molecular-weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate. Antimicrob Agents Chemother2001; 45: 3427–3432.
12.
Skoler-KarpoffS., RamjeeG., AhmedK.Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet2008; 372: 1977–1987.
13.
ZouG.A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol2004; 159: 702–706.
14.
TurvilleS.G., AravantinouM., MillerT.Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS ONE2008; 3: e3162.
